Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma

Thomsen, Hauke; Chattopadhyay, Subhayan; Weinhold, Niels; Vodička, Pavel; Vodičková, Ľudmila; Hoffmann, Per; Nöthen, Markus M.; Jöckel, Karl Heinz; Langer, Christian; Hallmans, Göran; Pettersson-Kymmer, Ulrika; Ohlsson, Claes; Späth, Florentin; Houlston, Richard S.; Goldschmidt, Hartmut; Hemminki, Kari; Försti, Asta

doi:10.1038/s41375-019-0396-x

Cited by 17 publications

(21 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…100 An increase in prevalence of such precursor diseases in relatives is therefore likely to be observed for myeloma and the myeloid malignancies with respect to the precursor lesion monoclonal gammopathy of unknown significance and clonal hematopoiesis, respectively. [101][102][103][104][105][106][107] Second, FRRs reflect the influence of all forms of family history on risk. Inevitably, this may include a subset with clear Mendelian inheritance.…”

Section: Discussionmentioning

confidence: 99%

Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk

Sud

Chattopadhyay

Thomsen

et al. 2019

Blood

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk

Sud

Chattopadhyay

Thomsen

et al. 2019

Blood

Self Cite

View full text Add to dashboard Cite

show abstract

“…A genetic correlation exists between MGUS and MM suggesting that the MM risk loci exert their biological effect, at least in part, before the establishment of MGUS and contribute to familial clustering. [58][59][60]85,86 Moreover, the shared genetic risk factors observed between MM with other B-cell malignancies such as AL amyloidosis and CLL suggests shared etiology and biology in oncogenesis. 87,88…”

Section: Germline Geneticsmentioning

confidence: 99%

Epidemiology, genetics and treatment of multiple myeloma and precursor diseases

Hemminki

Försti

Houlston

et al. 2021

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 people being diagnosed with MM per year. Whereas 5-year survival after a diagnosis of MM has improved from 28% in 1975 to 56% in 2012, the disease remains essentially incurable. In this review, we summarize our current understanding of MM including its epidemiology, genetics and biology. We will also provide an overview of MM management that has led to improvements in survival, including recent changes to diagnosis and therapies. Areas of unmet need include the management of patients with high-risk MM, those with reduced performance status and those refractory to standard therapies. Ongoing research into the biology and early detection of MM as well as the development of novel therapies, such as immunotherapies, has the potential to influence MM practice in the future.

show abstract

“…Another advantage of focusing on Sweden is its high level cancer registry which was among the first nationwide cancer registries in the world 17 . The combination of the early Swedish history on MM, tradition of disease epidemiology and open health care system stimulated us to describe nation-wide epidemiology of MM in comparison to other HNs as the previous studies by Swedish hematologists have focused on survival in MM only 10 , 11 , 18 . With analysis of the incidence/mortality/survival patterns we try to understand factors underlying improvements in survival in MM patients over a 50-year period in comparison to other HNs.…”

Section: Introductionmentioning

confidence: 99%

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016

Hemminki

Försti

Hansson

2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

Survival in multiple myeloma (MM) has developed favorably over the past decades for reasons that have been ascribed to new medications and treatment. However, development of survival over a long period and comparison to other hematopoietic neoplasms (HN) is less well known. Here we used Swedish cancer data from the Nordcan database, spanning a 50-year period from 1967 to 2016, and analyzed 1- and 5-year survival data. As a novel type of analysis we calculate the difference in survival between year 1 and 5 which indicates how well survival was maintained in the 4-year period following year 1 after diagnosis. The relative 1- and 5- year survival increased constantly; the 5-year survival graph for women was almost linear. The difference between 1- and 5-year survival revealed that the 5-year survival gain was entirely due to the improvement in 1-year survival, except for the last period. Survival improvement in all HNs exceeded that in MM. The linear 5-year survival increase for female MM patients suggests a contribution by many small improvements in the first year care rather than single major events. The future challenges are to push the gains past year 1 and to extend them to old patients.

show abstract

Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma

Cited by 17 publications

References 15 publications

Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk

Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk

Epidemiology, genetics and treatment of multiple myeloma and precursor diseases

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016

Contact Info

Product

Resources

About